Clinical trials: COVID19 ARDS
COVID-19, ARDS
Losartan and Spironolactone Treatment for ICU Patients With COVID-19 Suffering From ARDS
Coronavirus disease (COVID-19) is a current pandemic infection caused by an RNA virus called Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2).
- Trial name
- COVIDANCE (NCT04643691)
- Testing
- Losartan 50 mg and Spironolactone 25 mg pillules oral use
- Where
- France
- Volunteers
- 78 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Acute Respiratory Distress Syndrome
Pilot Clinical Study of NOA-001 for ARDS (Acute Respiratory Distress Syndrome)
The primary object of this clinical study is to investigate the efficacy and the safety of NOA-001 in patients with ARDS (ARDS caused by Non-COVID-19 or COVID-19).
- Trial name
- NCT04804943
- Testing
- NOA-001
- Where
- Japan
- Volunteers
- 45 people
- Sponsor
- Toray Industries, Inc
Covid19
A Phase 2b Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study, Evaluating Efficacy and Safety of Allocetra-OTS in Patients With Severe or Critical COVID-19 With Associated Acute Respiratory Distress Syndrome (ARDS)
This is a Phase 2b multi-center, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of intravenous (IV) Allocetra-OTS 10x10^9 cells vs placebo (1:1) in adult hospitalized patients with severe or…
- Trial name
- NCT04922957
- Testing
- ALLOCETRA-OTS
- Where
- Israel
- Volunteers
- 12 people
- Sponsor
- Enlivex Therapeutics Ltd.
COVID-19 (Coronavirus Disease 2019), COVID-19 Pandemic
University Hospital of Ioannina COVID-19 (Coronavirus Disease 2019) Registry
COVID-19 (Coronavirus Disease 2019) Registry of University Hospital of Ioannina. Retrospective datasource registry with quantitative and qualitative patient data from the hospital medical records.
- Conditions
- COVID-19 (Coronavirus Disease 2019), COVID-19 Pandemic, COVID-19 Pneumonia, COVID-19 Respiratory Infection
- Trial name
- NCT05534074
- Where
- Greece
- Volunteers
- 2,500 people
- Sponsor
- University Hospital, Ioannina
ARDS Due to COVID-19
Surfactant-BL in Adult Acute Respiratory Distress Syndrome Due to COVID-19
The purpose of this study is to prove the efficacy and safety Surfactant-BL, administered by inhalation in adult hospitalized patients with ARDS due to COVID-19.
- Trial name
- NCT04568018
- Testing
- Surfactant
- Where
- Russia
- Volunteers
- 120 people
- Sponsor
- Biosurf LLC.
COVID, Corona Virus Infection
RIC as an Adjunct Therapy for Severe COVID-19 Disease: a Prospective Randomized Pilot Study
This research aims to assess the use of an experimental and non-invasive procedure, Remote Ischemic Conditioning (RIC), as an adjunct therapy in attenuating severe COVID-19 disease.
- Conditions
- COVID, Corona Virus Infection, Acute Lung Injury, Ischemia Limb
- Trial name
- NCT04659460
- Testing
- Remote Ischemic Conditioning
- Volunteers
- 30 people
- Sponsor
- Unity Health Toronto
COVID-19, Hypoxia
Administration of Intravenous Vitamin C in Novel Coronavirus Infection (COVID-19) and Decreased Oxygenation
Previous research has shown that high dose intravenous vitamin C (HDIVC) may benefit patients with sepsis, acute lung injury (ALI), and the acute respiratory distress syndrome (ARDS).
- Trial name
- AVoCaDO (NCT04357782)
- Testing
- L-ascorbic acid
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Hunter Holmes Mcguire Veteran Affairs Medical Center
Pulmonary Fibrosis, COVID-19
Pulmonary Fibrosis After Severe COVID-19 Pneumonia
Patients discharged after hospitalization for COVID-19 pneumonia were retrospectively selected by radiologically established criteria that at admission presented at chest computed tomography (CT) (i) normal lung parenchyma <50%…
- Trial name
- SPIFFERO (NCT06423560)
- Testing
- Computed tomography
- Where
- Italy
- Volunteers
- 61 people
- Sponsor
- IRCCS San Raffaele
COVID-19 Acute Respiratory Distress Syndrome
Personalized Targeted Immunomodulation in COVID-19 ARDS
Rationale: In COVID19 single-targeted immunomodulation, mostly via an IL-6 receptor blocker, was used by a one-size fits all non-targeted approach. In future pandemics the same might occur.
- Trial name
- COMODULATE (NCT06311448)
- Testing
- Single target immunomodulation, Standard of care
- Where
- Netherlands
- Volunteers
- 164 people
- Sponsor
- Erasmus Medical Center
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Comparison of Non-invasive Oxygenation Strategies in Patients Admitted for Covid-19 Acute Respiratory Distress Syndrome
Acute Respiratory Distress Syndrome (ARDS) is the main clinical presentation of SARS-CoV-2 (Covid-19) infected patients admitted in Intensive Care Unit (ICU).
- Trial name
- SONIC-19 (NCT04725084)
- Testing
- Use of High Flow Nasal Cannula alone, Use of Non-invasive Ventilation, Use of Continuous Positive Airway Pressure
- Where
- 4 sites in France
- Volunteers
- 355 people
- Sponsor
- Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer
COVID, SARS-CoV-2
European/Euro-ELSO Survey on Adult and Neonatal/ Pediatric COVID-19 Patients in ECMO
In the last 10 years, severe acute respiratory infection (SARI) was responsible of multiple outbreaks putting a strain on the public health worldwide.
- Conditions
- COVID, SARS-CoV-2, ARDS, Human, Refractory Hypoxemia
- Trial name
- EuroECMO-COVID (NCT04366921)
- Where
- 97 sites in Austria, Belgium and 17 more
- Volunteers
- 150 people
- Sponsor
- Maastricht University Medical Center
Mesenchymal Stromal Cells, Remestemcel-L
MSCs in COVID-19 ARDS
The mortality rate in SARS-CoV-2-related severe ARDS is high despite treatment with antivirals, glucocorticoids, immunoglobulins, and ventilation.
- Conditions
- Mesenchymal Stromal Cells, Remestemcel-L, Acute Respiratory Distress Syndrome, COVID
- Trial name
- NCT04371393
- Testing
- Remestemcel-L
- Where
- 21 sites in United States
- Volunteers
- 223 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Acute Respiratory Distress Syndrome, COVID-19
A Study of Brexanolone for Acute Respiratory Distress Syndrome (ARDS) Due to Coronavirus Disease 2019 (COVID-19)
The purpose of this study was to evaluate the efficacy and safety of brexanolone in participants on ventilator support for acute respiratory distress syndrome (ARDS) due to COVID-19.
- Trial name
- NCT04537806
- Testing
- Brexanolone
- Where
- 9 sites in United States
- Volunteers
- 29 people
- Sponsor
- Sage Therapeutics
COVID-19 Acute Respiratory Distress Syndrome
Safety and Efficacy of Inhaled XW001 For Hospitalized COVID-19 Patients Requiring Oxygen Therapy
This is a multiregional, randomized, double-blind, placebo-controlled Phase 2 study in patients with confirmed symptomatic COVID-19, designed to evaluate the safety, tolerability, efficacy, and PK of XW001 (IL-29 analog)…
- Trial name
- NCT05083117
- Testing
- XW001
- Where
- 2 sites in Argentina, Peru
- Sponsor
- Sciwind Biosciences APAC CO Pty. Ltd.
COVID-19, Severe Respiratory Distress Syndrome
suPAR Michigan M2C2 Heterogeneity Validation Cohort Study
This is a retrospective, non interventional cohort study using stored plasma samples from appoximately 300 adults hospitalized with confirmed COVID 19.
- Conditions
- COVID-19, Severe Respiratory Distress Syndrome, Acute Respiratory Distress Syndrome
- Trial name
- NCT07466524
- Testing
- suPARnostic® TurbiLatex Assay on Roche cobas c501
- Where
- United States
- Volunteers
- 367 people
- Sponsor
- ViroGates A/S
Covid19
Selenium as a Potential Treatment for Moderately-ill, Severely-ill, and Critically-ill COVID-19 Patients.
Given its anti-viral, anti-oxidative, immune-enhancing, cytokine-modulating, and anticoagulant properties, the investigators hypothesize that Selenium infusion at supranutritional doses for moderately-ill, severely-ill, and…
- Trial name
- SeCOVID (NCT04869579)
- Testing
- Selenium (as Selenious Acid)
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- CHRISTUS Health
COVID-19, Acute Respiratory Distress Syndrome
Efficacy and Safety of aerosolizedDornase Alfa Administration in Patients With COVID19 Induced ARDS (COVIDORNASE)
This study plans to learn more about the effects of Dornase Alfa in COVID19 (coronavirus disease of 2019) patients, the medical condition caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
- Trial name
- COVIDORNASE (NCT04355364)
- Testing
- Dornase Alfa Inhalation Solution [Pulmozyme], standard procedure
- Where
- France
- Volunteers
- 77 people
- Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
Covid19
Apelin; ACE2 and Biomarkers of Alveolar-capillary Permeability in SARS-cov-2 (COVID-19).
Hypothesis: The apelin/APJ system is involved in the protection of the lung affected by the COVID-19 by interacting with the SARS-coV-2 entry door: the Angiotensin I Converting Enzyme 2 (ACE2) and the renin-angiotensin system…
- Trial name
- APEL-COVID (NCT04632732)
- Testing
- COVID-19 test, Blood sampling
- Where
- Canada
- Volunteers
- 140 people
- Sponsor
- Centre de recherche du Centre hospitalier universitaire de Sherbrooke
ARDS, COVID-19
Impact of Neck Inspiratory Muscle Activation During Sleep in ICU Patients After a COVID 19 ARDS
Most patients in intensive care units (ICUs) experience severe sleep disruption. Sleep disruption and sleep alteration may have an influence on the ability to breathe spontaneously.
- Trial name
- COVISLEEP (NCT04371029)
- Testing
- PSG
- Where
- France
- Volunteers
- 17 people
- Sponsor
- University Hospital, Bordeaux
Pneumonia, Viral
Assessment of the Risk of Pulmonary Embolism and Coagulation Profile in Patients With COVID-19 Lung Disease
The current severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic is complicated by pneumonia (15 to 20% of cases) requiring hospitalization with oxygen therapy.
- Trial name
- COVIDEP (NCT04479540)
- Testing
- Angiography scanner
- Where
- France
- Volunteers
- 117 people
- Sponsor
- Hopital Foch